These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 11015024

  • 21. The CHARM programme raises the profile of candesartan cilexetil in the treatment of chronic health failure.
    Cardiovasc J S Afr; 2004; 15(1):42-3. PubMed ID: 15095753
    [No Abstract] [Full Text] [Related]

  • 22. Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
    Noda M, Matsuo T, Nagano-Tsuge H, Ohta M, Sekiguchi M, Shibouta Y, Naka T, Imura Y.
    Jpn J Pharmacol; 2001 Apr; 85(4):416-22. PubMed ID: 11388646
    [Abstract] [Full Text] [Related]

  • 23. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension.
    Andersson OK, Neldam S.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S63-4. PubMed ID: 9331011
    [No Abstract] [Full Text] [Related]

  • 24. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
    Iimura O, Kusano E, Tanba K, Yanagiba S, Amemiya M, Ando Y, Honma S, Muto S, Asano Y.
    Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):439-44. PubMed ID: 14509219
    [Abstract] [Full Text] [Related]

  • 25. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.
    Noda M, Matsuo T, Fukuda R, Ohta M, Nagano H, Shibouta Y, Naka T, Nishikawa K, Imura Y.
    Kidney Int; 1999 Sep; 56(3):898-909. PubMed ID: 10469358
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and tolerability of candesartan cilexetil in special patient groups.
    Trenkwalder P.
    Blood Press Suppl; 2000 Sep; 1():27-30. PubMed ID: 11059633
    [Abstract] [Full Text] [Related]

  • 27. Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats.
    Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME.
    Clin Sci (Lond); 2001 Jun; 100(6):591-9. PubMed ID: 11352773
    [Abstract] [Full Text] [Related]

  • 28. Outcome studies in diabetic nephropathy.
    Mohanram A, Toto RD.
    Semin Nephrol; 2003 May; 23(3):255-71. PubMed ID: 12838494
    [Abstract] [Full Text] [Related]

  • 29. Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
    Eberhard R, Dikow R.
    Ann Med; 2002 May; 34(7-8):507-13. PubMed ID: 12553490
    [Abstract] [Full Text] [Related]

  • 30. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
    Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH.
    Nephrol Dial Transplant; 2002 Jun; 17(6):1019-24. PubMed ID: 12032191
    [Abstract] [Full Text] [Related]

  • 31. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
    McInnes GT, O'Kane KP, Jonker J, Roth J.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
    [Abstract] [Full Text] [Related]

  • 32. Role of the renin-angiotensin system in hypertension in the elderly.
    Nagano M, Higaki J, Mikami H, Ogihara T.
    Blood Press Suppl; 1994 Sep; 5():130-3. PubMed ID: 7889195
    [Abstract] [Full Text] [Related]

  • 33. Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison.
    Asmar R, Porcellati C, Dusing R.
    Drugs Exp Clin Res; 2004 Sep; 30(4):153-61. PubMed ID: 15553661
    [Abstract] [Full Text] [Related]

  • 34. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS.
    Blood Press Suppl; 2000 Sep; 1():19-22. PubMed ID: 11059631
    [Abstract] [Full Text] [Related]

  • 35. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S.
    Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
    [Abstract] [Full Text] [Related]

  • 36. Discordant responses to two classes of drugs acting on the renin-angiotensin system.
    Sever PS, Chang CL.
    J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1):25-30. PubMed ID: 11881062
    [Abstract] [Full Text] [Related]

  • 37. Achieving quality 24-h blood pressure control with candesartan cilexetil.
    Meredith P.
    Blood Press Suppl; 2000 Mar; 1():23-6. PubMed ID: 11059632
    [Abstract] [Full Text] [Related]

  • 38. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F.
    Blood Press Suppl; 2000 Mar; 1():36-9. PubMed ID: 11059635
    [Abstract] [Full Text] [Related]

  • 39. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [Abstract] [Full Text] [Related]

  • 40. Angiotensin II receptor blockers and nephropathy trials.
    Bloomgarden ZT.
    Diabetes Care; 2001 Oct; 24(10):1834-8. PubMed ID: 11574450
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.